Chronic granulomatous disease: Overview and hematopoietic stem cell transplantation

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 6, 2011, Pages 1319-1326

  Kang, Elizabeth M ^a   Marciano, Betty E ^a   Deravin, Suksee ^a   Zarember, Kol A ^a   Holland, Steven M ^a   Malech, Harry L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

allogeneic hematopoietic transplantation; autoimmune; Chronic granulomatous disease; infection; inflammation

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN; ANTIFUNGAL AGENT; AZATHIOPRINE; BUSULFAN; CEPHALOSPORIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISONE; PYRROLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; SALAZOSULFAPYRIDINE; THYMOCYTE ANTIBODY; TRIMETHOPRIM; VORICONAZOLE;

ACTINOMYCOSIS; ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ANTIPHOSPHOLIPID SYNDROME; AREA UNDER THE CURVE; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BURKHOLDERIA CEPACIA INFECTION; CHRONIC GRANULOMATOUS DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; ENTERITIS; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; GRANULOMATOUS INFLAMMATION; HEPATITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A NEPHROPATHY; INVASIVE ASPERGILLOSIS; IRRITABILITY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KLEBSIELLA INFECTION; LIVER ABSCESS; LOW DRUG DOSE; LUNG BIOPSY; LUNG INFECTION; LUNG MYCOSIS; LUPUS VULGARIS; LYMPHADENITIS; MELANOMA; MORBIDITY; MORTALITY; MYALGIA; MYCOSIS; NOCARDIOSIS; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SEPSIS; SERRATIA INFECTION; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

AUTOIMMUNITY; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; INFLAMMATION; MUTATION; NADPH OXIDASE; TRANSPLANTATION, HOMOLOGOUS;

EID: 79957875084     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.03.028     Document Type: Review

References (91)

1. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998;77:345-54. (Pubitemid 28449835)
2. Matute JD, Arias AA, Wright NA, Wrobel I, Waterhouse CC, Li XJ, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-15.
3. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010;363:2600-10.
4. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol 2008;126:155-64.
5. Kobayashi S, Murayama S, Takanashi S, Takahashi K, Miyatsuka S, Fujita T, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr 2008;167: 1389-94.
6. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O'Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004;114:462-8. (Pubitemid 39006676)
7. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
8. Vinh DC, Shea YR, Jones PA, Freeman AF, Zelazny A, Holland SM. Chronic invasive aspergillosis caused by Aspergillus viridinutans. Emerg Infect Dis 2009;15: 1292-4.
9. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One 2009;4:e5234.
10. Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog 2006;2:e28.
11. Reichenbach J, Lopatin U, Mahlaoui N, Beovic B, Siler U, Zbinden R, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis 2009;49:1703-10.
12. Vinh DC, Shea YR, Sugui JA, Parrilla-Castellar ER, Freeman AF, Campbell JW, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49:102-11.
13. Messina CG, Reeves EP, Roes J, Segal AW. Catalase negative Staphylococcus aureus retain virulence in mouse model of chronic granulomatous disease. FEBS Lett 2002;518:107-10. (Pubitemid 34454973)
14. Dorman SE, Guide SV, Conville PS, DeCarlo ES, Malech HL, Gallin JI, et al. Nocardia infection in chronic granulomatous disease. Clin Infect Dis 2002;35: 390-4. (Pubitemid 34852568)
15. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005;40:1684-8. (Pubitemid 40720823)
16. Huang YF, Liu SY, Yen CL, Yang PW, Shieh CC. Thapsigargin and flavin adenine dinucleotide ex vivo treatment rescues trafficking-defective gp91phox in chronic granulomatous disease leukocytes. Free Radic Biol Med 2009;47:932-40.
17. Brechard S, Tschirhart EJ. Regulation of superoxide production in neutrophils: role of calcium influx. J Leukoc Biol 2008;84:1223-37.
18. Lublin M, Bartlett DL, Danforth DN, Kauffman H, Gallin JI, Malech HL, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 2002; 235:383-91. (Pubitemid 34183889)
19. Yamazaki-Nakashimada MA, Stiehm ER, Pietropaolo-Cienfuegos D, Hernandez-Bautista V, Espinosa-Rosales F. Corticosteroid therapy for refractory infections in chronic granulomatous disease: case reports and review of the literature. Ann Allergy Asthma Immunol 2006;97:257-61. (Pubitemid 44272596)
20. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000;79: 170-200. (Pubitemid 30327531)
21. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003;348:2416-22. (Pubitemid 36682820)
22. Beaute J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux ME, Mouy R, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2010 [Epub ahead of print].
23. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994;125:998-1003. (Pubitemid 24379140)
24. Sanchez-Ortega I, Patino B, Arnan M, Peralta T, Parody R, Gudiol C, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2010[Epub ahead of print].
25. Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010;62: 31-7.
26. Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010;146:300-4.
27. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991;324:509-16.
28. Mouy R, Seger R, Bourquin JP, Veber F, Blanche S, Griscelli C, et al. Interferon gamma for chronic granulomatous disease. N Engl J Med 1991;325:1516-7.
29. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692-9. (Pubitemid 39180442)
30. De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol 2008;122:1097-103.
31. Ameratunga R, Woon ST, Vyas J, Roberts S. Fulminant mulch pneumonitis in undiagnosed chronic granulomatous disease: a medical emergency. Clin Pediatr (Phila) 2010;49:1143-6.
32. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. J Exp Med 1997;185:207-18. (Pubitemid 27078278)
33. Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007;45:673-81. (Pubitemid 47378879)
34. Brown KL, Bylund J, MacDonald KL, Song-Zhao GX, Elliott MR, Falsafi R, et al. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin Immunol 2008; 129:90-102.
35. Segal BH, Han W, Bushey JJ, Joo M, Bhatti Z, Feminella J, et al. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One 2010;5:e9631.
36. Foster MH, Fitzsimons MM. Lupus-like nephrotropic autoantibodies in nonautoimmune mice harboring an anti-basement membrane/anti-DNA Ig heavy chain transgene. Mol Immunol 1998;35:83-94. (Pubitemid 28300490)
37. Yamamoto A, Taniuchi S, Tsuji S, Hasui M, Kobayashi Y. Role of reactive oxygen species in neutrophil apoptosis following ingestion of heat-killed Staphylococcus aureus. Clin Exp Immunol 2002;129:479-84. (Pubitemid 35024917)
38. Frasch SC, Berry KZ, Fernandez-Boyanapalli R, Jin HS, Leslie C, Henson PM, et al. NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of activated and dying neutrophils via G2A. J Biol Chem 2008;283: 33736-49.
39. Arroyo A, Modriansky M, Serinkan FB, Bello RI, Matsura T, Jiang J, et al. NADPH oxidase-dependent oxidation and externalization of phosphatidylserine during apoptosis in Me2SO-differentiated HL-60 cells. Role in phagocytic clearance. J Biol Chem 2002;277:49965-75. (Pubitemid 36014447)
40. Fernandez-Boyanapalli R, McPhillips KA, Frasch SC, Janssen WJ, Dinauer MC, Riches DW, et al. Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma in a nitric oxidedependent manner. J Immunol 2010;185:4030-41.
41. Fernandez-Boyanapalli R, Frasch SC, Riches DW, Vandivier RW, Henson PM, Bratton DL. PPARg activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 2010;116:4512-22.
42. Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, Vandivier RW, Harry BL, Riches DW, et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 2009;113:2047-55.
43. Lekstrom-Himes JA, Kuhns DB, Alvord WG, Gallin JI. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J Immunol 2005;174:411-7. (Pubitemid 40007429)
44. Fadok VA, Bratton DL, Guthrie L, Henson PM. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol 2001;166:6847-54. (Pubitemid 32467230)
45. Gallin JI, Buescher ES. Abnormal regulation of inflammatory skin responses in male patients with chronic granulomatous disease. Inflammation 1983;7: 227-32. (Pubitemid 14155225)
46. Jackson SH, Gallin JI, Holland SM. The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med 1995;182:751-8.
47. Segal BH, Kuhns DB, Ding L, Gallin JI, Holland SM. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol 2002;71:410-6.
48. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010;51:1429-34.
49. Gungor T, Halter J, Klink A, Junge S, Stumpe KD, Seger R, et al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation 2005;79:1596-606. (Pubitemid 40847593)
50. Klaudel-Dreszler MA, Kalwak K, Kurenko-Deptuch M, Wolska-Kusnierz B, Heropolitanska-Pliszka E, Pietrucha B, et al. Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. Int J Hematol 2009;90:571-5.
51. Honig M, Flegel WA, Schwarz K, Freihorst JF, Baumann U, Seltsam A, et al. Successful hematopoietic stem-cell transplantation in a patient with chronic granulomatous disease and McLeod phenotype sensitized to Kx and K antigens. Bone Marrow Transplant 2010;45:209-11.
52. Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M, et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009;43:469-76.
53. Kansoy S, Kutukculer N, Aksoylar S, Aksu G, Kantar M, Cetingul N. Successful bone marrow transplantation in an 8-month-old patient with chronic granulomatous disease. Turk J Pediatr 2006;48:253-5. (Pubitemid 44697282)
54. Kikuta A, Ito M, Mochizuki K, Akaihata M, Nemoto K, Sano H, et al. Nonmyeloablative stem cell transplantation for nonmalignant diseases in children with severe organ dysfunction. Bone Marrow Transplant 2006;38:665-9. (Pubitemid 44669681)
55. Kordes U, Binder TM, Eiermann TH, Hassenpflug-Diedrich B, Hassan MA, Beutel K, et al. Successful donor-lymphocyte infusion for extreme immune-hemolysis following unrelated BMT in a patient with X-linked chronic granulomatous disease and McLeod phenotype. Bone Marrow Transplant 2008;42:219-20.
56. Miki M, Ono A, Awaya A, Miyagawa S, Onodera R, Kurita E, et al. Successful bone marrow transplantation in chronic granulomatous disease. Pediatr Int 2009; 51:838-41.
57. Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders. Bone Marrow Transplant 2008;42:83-91.
58. Petrovic A, Dorsey M, Miotke J, Shepherd C, Day N. Hematopoietic stem cell transplantation for pediatric patients with primary immunodeficiency diseases at All Children's Hospital/University of South Florida. Immunol Res 2009;44:169-78.
59. Rappeport JM, Newburger PE, Goldblum RM, Goldman AS, Nathan DG, Parkman R. Allogeneic bone marrow transplantation for chronic granulomatous disease. J Pediatr 1982;101:952-5. (Pubitemid 13253252)
60. Ringden O, Remberger M, Svenberg P, Svahn BM, Dahllof G, Gustafsson B, et al. Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of nonmalignant diseases. Bone Marrow Transplant 2007;39:383-8. (Pubitemid 46487302)
61. Sastry J, Kakakios A, Tugwell H, Shaw PJ. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer 2006;47:327-9. (Pubitemid 44148051)
62. Schuetz C, Hoenig M, Gatz S, Speth F, Benninghoff U, Schulz A, et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res 2009;44:35-41.
63. Schuetz C, Hoenig M, Schulz A, Lee-Kirsch MA, Roesler J, Friedrich W, et al. Successful unrelated bone marrow transplantation in a child with chronic granulomatous disease complicated by pulmonary and cerebral granuloma formation. Eur J Pediatr 2007;166:785-8. (Pubitemid 46988167)
64. Suzuki N, Hatakeyama N, Yamamoto M, Mizue N, Kuroiwa Y, Yoda M, et al. Treatment of McLeod phenotype chronic granulomatous disease with reduced-intensity conditioning and unrelated-donor umbilical cord blood transplantation. Int J Hematol 2007;85:70-2. (Pubitemid 46193292)
65. Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002;100:4344-50.
66. Soncini E, Slatter MA, Jones LBKR, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol 2009;145:73-83.
67. Del Giudice I, Iori AP, Mengarelli A, Testi AM, Romano A, Cerretti R, et al. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol 2003;82:189-92. (Pubitemid 36701004)
68. Yokoyama S, Kasahara M, Fukuda A, Sato S, Mori T, Nakagawa A, et al. Successful living-donor liver transplantation for chronic hepatic graft-versus-host disease after bone marrow transplantation for chronic granulomatous disease. Transplantation 2008;86:367-8.
69. Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001;344:881-8. (Pubitemid 32224396)
70. Soncini E, Slatter M, Jones L, Hughes S, Flood T, Barge D, et al. Haematopoeitic stem cell transplantation for chronic granulomatous disease - a single-centre experience. Bone Marrow Transplantation 2008;41(suppl):S28.
71. Gungor T, Albert M, Schanz U, Slater M, Gennery A, Waver A, et al. Successful low-dose busulfan/ full-dose fludarabine based reduced intensity conditioning in high risk pediatric and adult chronic ganulomatous disease patients. Presented at: XIVth Meeting of the European Society for Immunodeficiencies; 2010; Istanbul, Turkey.
72. Kang EM, Kelly C, Hilligoss D, Marquesen M, DeCastro R, Wilder J, et al. A novel non-myeloablative regimen for related and unrelated allogeneic transplantation of high risk patients with chronic granulomatous disease (CGD). Biol Blood Marrow Transplant 2011;17:1.
73. Nakano T, Boku E, Yoshioka A, Fukimara Y. A case of McLeod phenotype chronic granulomatous disease who received unrelated cord blood transplantation. J Pediatr Hematol 1999;12:264.
74. Jaing TH, Lee WI, Cheng PJ, Chen SH, Huang JL, Soong YK. Successful unrelated donor cord blood transplantation for chronic granulomatous disease. Int J Hematol 2010;91:670-2.
75. Mochizuki K, Kikuta A, Ito M, Akaihata M, Sano H, Ohto H, et al. Successful unrelated cord blood transplantation for chronic granulomatous disease: a case report and review of the literature. Pediatr Transplant 2009;13:384-9.
76. Parikh SH, Szabolcs P, Prasad VK, Lakshminarayanan S, Martin PL, Driscoll TA, et al. Correction of chronic granulomatous disease after second unrelated-donor umbilical cord blood transplantation. Pediatr Blood Cancer 2007;49:982-4. (Pubitemid 350022456)
77. Bhattacharya A, Slatter M, Curtis A, Chapman CE, Barge D, Jackson A, et al. Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 2003;31:403-5. (Pubitemid 36410688)
78. Reichenbach J, Van de Velde H, De Rycke M, Staessen C, Platteau P, Baetens P, et al. First successful bone marrow transplantation for X-linked chronic granulomatous disease by using preimplantation female gender typing and HLA matching. Pediatrics 2008;122:e778-82.
79. Goussetis E, Konialis CP, Peristeri I, Kitra V, Dimopoulou M, Petropoulou T, et al. Successful hematopoietic stem cell transplantation in 2 children with X-linked chronic granulomatous disease from their unaffected HLA-identical siblings selected using preimplantation genetic diagnosis combined with HLA typing. Biol Blood Marrow Transplant 2010;16:344-9.
80. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-7. (Pubitemid 40170912)
81. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010;116:4693-9.
82. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, et al. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biol BloodMarrowTransplant 2010[Epub ahead of print].
83. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004;10:178-85. (Pubitemid 38262880)
84. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550-8. (Pubitemid 39166537)
85. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104:961-8. (Pubitemid 39038014)
86. Feld JJ, Hussain N, Wright EC, Kleiner DE, Hoofnagle JH, Ahlawat S, et al. Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease. Gastroenterology 2008;134:1917-26. (Pubitemid 351783257)
87. Borge DP, DeCastro R, Theobald N, Malech H, Leitman S, Kang EM. Successful control of preexistent active infection by granulocyte transfusions during conditioning induced cytopenia in patient with chronic granulomatous disease undergoing hematopoietic stem cell transplant. Blood 2010;116:1329.
88. Grez M, Reichenbach J, Schwable J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 2011;19:28-35.
89. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12: 401-9.
90. Kang EM, Choi U, Theobald N, Linton G, Long Priel DA, Kuhns D, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010;115:783-91.
91. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-3. (Pubitemid 34734219)